Skip to main content

Advertisement

SpringerLink
Log in

Predictors of Survival in Patients With Bone Metastasis of Lung Cancer

  • Original Article
  • Tumor
  • Published:
Clinical Orthopaedics and Related Research

Abstract

The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1–74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis.

Level of Evidence: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Agarwala AK, Hanna NH. Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer. 2005;6:367–368.

    PubMed  Google Scholar 

  2. Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K, Hasegawa Y. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res. 1999;90:249–253.

    PubMed  CAS  Google Scholar 

  3. Batson OV. The function of vertebral veins and their role in spread of metastases. Ann Surg. 1940;112:138–149.

    Article  PubMed  CAS  Google Scholar 

  4. Freise G, Gabler A, Liebig S. Bronchial carcinoma and long-term survival: retrospective study of 433 patients who underwent resection. Thorax. 1978;33:228–234.

    Article  PubMed  CAS  Google Scholar 

  5. Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, Nilsson J, Walloe A, Kalén A, Wedin R. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl. 2004;75:11–15.

    Article  PubMed  CAS  Google Scholar 

  6. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815–3825.

    Article  PubMed  CAS  Google Scholar 

  7. Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg. 2005;11:401–404.

    PubMed  Google Scholar 

  8. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–139.

    Article  PubMed  Google Scholar 

  9. Johnston AD. Pathology of metastatic tumors in bone. Clin Orthop Relat Res. 1970;73:8–32.

    Article  PubMed  CAS  Google Scholar 

  10. Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br. 2005;87:698–703.

    Article  PubMed  CAS  Google Scholar 

  11. Matsuyama W, Yamamoto M, Machida K, Mitsuyama H, Watanabe M, Higashimoto I, Osame M, Arimura K. [Two lung adenocarcinoma patients with multiple brain metastasis treated with gefitinib and surviving more than 2 years] (in Japanese). Nihon Kokyuki Gakkai Zasshi. 2006;44:653–658.

    PubMed  Google Scholar 

  12. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23:2513–2520.

    Article  PubMed  CAS  Google Scholar 

  13. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–1717

    Article  PubMed  CAS  Google Scholar 

  14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.

    Article  PubMed  CAS  Google Scholar 

  15. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980;65:25–32.

    PubMed  CAS  Google Scholar 

  16. Tofe AJ, Francis MD, Harvey WJ. Correlation of neoplasms with incidence and localization of skeletal metastases: an analysis of 1,355 diphosphonate bone scans. J Nucl Med. 1975;16:986–989.

    PubMed  CAS  Google Scholar 

  17. Tokuhashi Y, Matsuzaki H, Toriyama S, Kawano H, Ohsaka S. Scoring system for the preoperative evaluation of metastatic spine tumor prognosis. Spine. 1990;15:1110–1113.

    Article  PubMed  CAS  Google Scholar 

  18. Tomita K, Kawahara N, Baba H, Tsuchiya H, Nagata S, Toribatake Y. Total en bloc spondylectomy for solitary spinal metastases. Int Orthop. 1994;18:291–298.

    Article  PubMed  CAS  Google Scholar 

  19. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine. 2001;26:298–306.

    Article  PubMed  CAS  Google Scholar 

  20. van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW. Dutch Bone Metastasis Study Group. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer. 2005;103:320–328.

    Article  PubMed  Google Scholar 

  21. Yokouchi H, Yamazaki K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer. 2007;7:51.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank Mitsuko Yokouchi and Kiyonori Kuriki for statistical assistance and Shoko Miyachi for administrative assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Orthopaedic Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan

    Hideshi Sugiura MD & Kenji Yamada MD

  2. Department of Respiratory Disease, Aichi Circulation and Respiratory Center, Nagoya City, Japan

    Takahiko Sugiura MD

  3. Department of Respiratory Disease, Aichi Cancer Center, Nagoya City, Japan

    Toyoaki Hida MD

  4. Department of Thoracic Surgery, Aichi Cancer Center, Nagoya City, Japan

    Tetsuya Mitsudomi MD

Authors
  1. Hideshi Sugiura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenji Yamada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiko Sugiura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toyoaki Hida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tetsuya Mitsudomi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideshi Sugiura MD.

Additional information

One or more of the authors (HS) has received funding from the Grant-in-Aid for Cancer Research (14–16) from the Ministry of Health, Labour and Welfare, Japan.

Each author certifies that his or her institution has approved or waived approval for the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.

About this article

Cite this article

Sugiura, H., Yamada, K., Sugiura, T. et al. Predictors of Survival in Patients With Bone Metastasis of Lung Cancer. Clin Orthop Relat Res 466, 729–736 (2008). https://doi.org/10.1007/s11999-007-0051-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11999-007-0051-0

Keywords

Search

Navigation